TY - JOUR
T1 - Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
AU - Mundell, Niamh
AU - Owen, Patrick J.
AU - Dalla Via, Jack
AU - Macpherson, Helen
AU - Daly, Robin
AU - Fraser, Steve
N1 - Publisher Copyright:
©
PY - 2021/12/30
Y1 - 2021/12/30
N2 - Objectives We investigated whether there were differences in associations between cognition with muscle strength, fitness and function in men with prostate cancer (PCa) treated with, and without androgen deprivation therapy (ADT) and non-PCa controls. A secondary aim was to compare differences in the prevalence of cognitive impairment. Design This cross-sectional study compared 70 ADT-treated men with PCa aged 50-85 years to non-ADT-treated men (n=52) and non-PCa controls (n=70). Setting University clinical exercise laboratory. Interventions Nil. Primary and secondary outcome measures Standardised assessments were conducted for cognition (learning, memory, attention, processing speed and executive function), muscle strength (grip strength and leg press), fitness (400 m walk), gait speed (4 m walk) and dual-tasking mobility (timed-up-and-go with a cognitive task). Results ADT-treated men showed stronger associations between fitness and executive function and task switching relative to controls (both: p≤0.03). For both PCa groups (independent of ADT use), poorer dual-task mobility was more strongly associated with decreased psychomotor attention (both: p≤0.027) and global cognitive function (both: p≤0.031) compared with non-PCa controls. The overall prevalence of cognitive impairment was low (4%-13%) and did not differ between the groups. Conclusions The presence of PCa, with or without ADT treatment, did not increase the risk of cognitive impairment relative to non-PCa controls, yet did alter the associations between physical fitness and some measures of functional performance with certain cognitive domains. This highlights the importance of men with PCa maintaining fitness and functional capacity to optimise cognitive health. Trial registration number This study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12614000317695).
AB - Objectives We investigated whether there were differences in associations between cognition with muscle strength, fitness and function in men with prostate cancer (PCa) treated with, and without androgen deprivation therapy (ADT) and non-PCa controls. A secondary aim was to compare differences in the prevalence of cognitive impairment. Design This cross-sectional study compared 70 ADT-treated men with PCa aged 50-85 years to non-ADT-treated men (n=52) and non-PCa controls (n=70). Setting University clinical exercise laboratory. Interventions Nil. Primary and secondary outcome measures Standardised assessments were conducted for cognition (learning, memory, attention, processing speed and executive function), muscle strength (grip strength and leg press), fitness (400 m walk), gait speed (4 m walk) and dual-tasking mobility (timed-up-and-go with a cognitive task). Results ADT-treated men showed stronger associations between fitness and executive function and task switching relative to controls (both: p≤0.03). For both PCa groups (independent of ADT use), poorer dual-task mobility was more strongly associated with decreased psychomotor attention (both: p≤0.027) and global cognitive function (both: p≤0.031) compared with non-PCa controls. The overall prevalence of cognitive impairment was low (4%-13%) and did not differ between the groups. Conclusions The presence of PCa, with or without ADT treatment, did not increase the risk of cognitive impairment relative to non-PCa controls, yet did alter the associations between physical fitness and some measures of functional performance with certain cognitive domains. This highlights the importance of men with PCa maintaining fitness and functional capacity to optimise cognitive health. Trial registration number This study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12614000317695).
KW - clinical physiology
KW - delirium & cognitive disorders
KW - neurological oncology
KW - rehabilitation medicine
KW - sports medicine
KW - urological tumours
UR - http://www.scopus.com/inward/record.url?scp=85122641444&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-058478
DO - 10.1136/bmjopen-2021-058478
M3 - Article
C2 - 36415046
AN - SCOPUS:85122641444
SN - 2044-6055
VL - 11
JO - BMJ Open
JF - BMJ Open
IS - 12
M1 - e058478
ER -
